Invitae today announced full access to its Personalized Cancer Monitoring (PCMTM) platform to help detect minimal or molecular residual disease (MRD) in patients with solid tumors. Invitae PCM uses a novel set of personalized assays based on a patient’s tumor to detect circulating tumor DNA (ctDNA) in blood, offering the ability to perform risk stratification,…
eTurboNews články sú len pre predplatiteľov. Predplatné je ZADARMO.
Odberatelia sa prihlasujú tu Kliknite sem a prihláste sa na odber ZDARMA
Odberatelia sa prihlasujú tu Kliknite sem a prihláste sa na odber ZDARMA
ČO SI Z TOHTO ČLÁNKU ODniesť:
- Invitae PCM uses a novel set of personalized assays based on a patient’s tumor to detect circulating tumor DNA (ctDNA) in blood, offering the ability to perform risk stratification,….
- Invitae today announced full access to its Personalized Cancer Monitoring (PCMTM) platform to help detect minimal or molecular residual disease (MRD) in patients with solid tumors.
- eTurboNews články sú len pre predplatiteľov.
